Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $616.18: Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer.
Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases, with $14.3B in 2025 revenues and $4.5B net income. Its two largest revenue drivers are Dupixent (dupilumab; $17.8B global sales... Read more
Sell if holding. Multiple concerning factors at $616.18: Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 6.0/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Regeneron Pharmaceuticals, Inc.
Latest news
- NEWS Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's — Barron's negative
- NEWS Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug - Investor's Business Daily — Investor's Business Daily negative
- NEWS Regeneron Slumps On Unexpected Eylea Setback - Investor's Business Daily — Investor's Business Daily negative
- NEWS Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey — TradingKey negative
- NEWS Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com — Investing.com positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartySanofi10-K Item 1: 'the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated'
- HIGHcounterpartyBayer10-K Item 1: 'the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $616.18: Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $583.54. Score 6.0/10, moderate confidence.
Take-profit target: $749.98 (+21.7% upside). Prior stop was $583.54. Stop-loss: $583.54.
Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer; Leverage penalty (D/E 8.6): -1.5.
Regeneron Pharmaceuticals, Inc. trades at a P/E of 14.9 (forward 11.4). TrendMatrix value score: 7.3/10. Verdict: Sell.
38 analysts cover REGN with a consensus score of 3.9/5. Average price target: $833.
What does Regeneron Pharmaceuticals, Inc. do?Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes...
Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases, with $14.3B in 2025 revenues and $4.5B net income. Its two largest revenue drivers are Dupixent (dupilumab; $17.8B global sales recorded by Sanofi, Regeneron receives profit share) and EYLEA/EYLEA HD (aflibercept; $7.9B combined, U.S. recorded by Regeneron, ex-U.S. by Bayer). Regeneron operates a large human genetics database and collaborates with Sanofi and Bayer on its two flagship product franchises.